JAC Advance Access originally published online on June 12, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 61-64
© 2003 The British Society for Antimicrobial Chemotherapy
Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus
1 Public Health Research Institute, 225 Warren St., Newark, NJ 07103, USA; 2 Departments of Clinical Microbiology, St. Paul’s Hospital (Grey Nuns’) and Saskatoon and District Health; Department of Pathology, Royal University Hospital and the Department of Microbiology and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Received 11 November 2002; returned 18 January 2003; revised 4 March 2003; accepted 2 April 2003
The effect of antimicrobial concentration on colony-forming ability of resistant mutant subpopulations of Mycobacterium smegmatis and Staphylococcus aureus was measured for chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline. The relationship between drug concentration and the recovery of mutant colonies was distinct for each bacterium–antimicrobial combination; however, in each case application of large numbers of cells to drug-containing agar plates revealed a progressive reduction in mutant recovery as antimicrobial concentration increased. The minimal concentration that allowed no mutant recovery from more than 1010 input cells was measured to estimate the minimum inhibitory concentration (MIC) of the least susceptible, single-step mutant subpopulation, a parameter also called the mutant prevention concentration (MPC). These data expand the number of antimicrobial–bacterial combinations for which a mutant selection window can be measured.
Keywords: erythromycin, moxifloxacin, penicillin, tetracycline, chloramphenicol
* Corresponding author. Tel: +1-973-854-3360; Fax: +1-973-854-3101; E-mail: drlica{at}phri.org
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. E. T. Stearne, W. H. F. Goessens, J. W. Mouton, and I. C. Gyssens Effect of Dosing and Dosing Frequency on the Efficacy of Ceftizoxime and the Emergence of Ceftizoxime Resistance during the Early Development of Murine Abscesses Caused by Bacteroides fragilis and Enterobacter cloacae Mixed Infection Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3605 - 3611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. F. Goessens, J. W. Mouton, M. T. ten Kate, A. J. Bijl, A. Ott, and I. A. J. M. Bakker-Woudenberg Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection J. Antimicrob. Chemother., March 1, 2007; 59(3): 507 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Marcusson, S. K. Olofsson, P. K. Lindgren, O. Cars, and D. Hughes Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli J. Antimicrob. Chemother., June 1, 2005; 55(6): 938 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J Epstein, J. G Gums, and K. Drlica The Changing Face of Antibiotic Prescribing: The Mutant Selection Window Ann. Pharmacother., October 1, 2004; 38(10): 1675 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Drlica The mutant selection window and antimicrobial resistance J. Antimicrob. Chemother., July 1, 2003; 52(1): 11 - 17. [Abstract] [Full Text] [PDF]
|
|